Israel - English - Ministry of Health

taro pharmaceutical industries ltd - etodolac - capsules - etodolac 200 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. for the management of pain.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - etodolac - capsules - etodolac 300 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis. for the management of pain.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - etodolac - tablets - etodolac 500 mg - etodolac - etodolac - for the managament of signs and symptoms of osteoarthritis and rheumatoid arthritis.for the management of pain.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - etodolac - tablets extended release - etodolac 600 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthritis and rheumatoid arthritis.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - etodolac - tablets extended release - etodolac 400 mg - etodolac - etodolac - for the management of signs and symptoms of osteoarthrities and rheumatoid arthritis.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - naproxen - tablets - naproxen 500 mg - naproxen - naproxen - - relief of the signs and symptoms of rheumatic diseases including osteoarthritis ankylosing spondylitis of rheumatoid arthritis both in the treatment of acute flares and in the long-term management of the disease. - juvenile rheumatoid arthritis. - periarticular and musculoskeletal disorders - relief of pain in bursitis tendinitis synovitis tenosynovitis and lumbago. - relief of pain swelling tenderness and fever in acute gouty arthritis. - relief of symptoms of primary dysmenorrhea.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid - capsules - valproic acid 200 mg - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid - capsules - valproic acid 200 mg - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - valproic acid as sodium - syrup - valproic acid as sodium 200 mg / 5 ml - valproic acid - valproic acid - sole or adjunctive therapy in the treatment of simple (petit mal) and complex absence seizures. valporal may also be used adjunctively in patients with multiple seizure types which include absence seizures.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.32 mg (equivalent: estradiol, qty 2.25 mg) - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; isopropyl palmitate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and section 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.